Definitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis by unknown
RESEARCH Open Access
Definitive radiotherapy alone over 60 Gy
for patients unfit for combined treatment
to stage II-III non-small cell lung cancer:
retrospective analysis
Ji Hyeon Joo1, Si Yeol Song1,2*, Su Ssan Kim1, Yuri Jeong1, Seong-Yun Jeong2, Wonsik Choi3 and Eun Kyung Choi1,2*
Abstract
Background: Elderly patients with non-small cell lung cancer (NSCLC) are frequently treated with radiation therapy
(RT) alone, due to poor performance status or underlying disease. We investigated the effectiveness of RT over
60 Gy administered alone to NSCLC patients who were unfit or rejecting for combination treatment.
Methods and materials: From April 2002 to July 2010, 83 patients with stage II-III NSCLC, aged over 60 years,
treated by RT alone with a curative aim were analyzed. Radiation was targeted to the primary tumor and clinically
involved lymph nodes. A total dose of 66 Gy in 30 fractions (2.2 Gy/fraction) was delivered once daily (5 fractions
weekly). One month after completing RT, initial tumor responses were evaluated.
Results: Median age of patients was 73 years (range, 60 – 82 years). The median survival time was 18.6 months
(range, 2–135). The actuarial overall survival rates at 2 and 3 years were 39 % and 23 %, and cause-specific survival rate
at 2 and 3 years were 57 % and 47 %, respectively. When primary tumor was controlled, the 2- and 3-year CSS were
56 % and 45 %, but 32 % and 23 % in those patients with local failure, respectively (P = 0.017). Additionally, the local
control rate was associated with the initial tumor response (P = 0.01). No patient experienced grade 4+ toxicity.
Conclusions: For stage II-III NSCLC patients aged over 60 years and unfit or rejecting for combination treatment, RT
alone showed promising result. Long-term disease control can be expected if an early tumor response to radiation is
achieved, which could result in improved overall survival rates.
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Background
Non-small cell lung cancer (NSCLC) primarily occurs
in elderly patients, with a median age at diagnosis of
70 years; patients 80 years or older account for 14 %
of all NSCLC patients [1, 2]. The prevalence of these
cases and the resulting increased societal burden will
increase as life expectancy continually improves. Patients
diagnosed at advanced stages or who are medically in-
operable typically receive chemotherapy and radiation
therapy (RT), as randomized prospective studies have
demonstrated a survival advantage for the combination
of these modalities [3–5]. Despite the clear benefit,
elderly patients frequently have been undertreated or
do not receive chemotherapy [2]. One explanation is
the poor performance status of elderly patients, which
leads to intolerance to cytotoxic chemotherapy. Second,
elderly patients show more pronounced chemotherapy-
related toxicities, such as myelosuppression or pneumon-
itis [6].
Long-term survival of RT alone in inoperable NSCLC
is poor, estimated at around 5 %. But, most reports of
RT alone therapies for advanced NSCLC are outdated, as
they involve 2-dimensional treatments and relatively low
radiation doses (<60 Gy) [7–10]. Our present study
aimed to review treatment results following modern RT
techniques. The included patients were treated by RT
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alone using a 3-dimensional-conformal radiation therapy
(3D-CRT), high radiation doses, and involved-field ap-
proaches. And, intensity-modulated RT (IMRT), image-
guided RT (IGRT) or respiratory gating during treatment
were used in selected cases, to minimize toxicities.
In this study, we investigated the efficacy and toxicity
of RT alone in patients aged over 60 years with stage
II-III NSCLC. With this, we aimed to discuss on the
clinical outcome and find ways to increase recurrence-free
survival time, in elderly NSCLC patients.
Methods
Patients
This study was approved by the Asan Medical Center
Institutional Review Board (2012–0733). We retrospect-
ively reviewed 112 patients with stage II-III NSCLC,
aged over 60 years and were treated using conventional
RT alone, from April 2002 to July 2010. Among these
patients, 29 were excluded in the analysis with following
reasons: follow-up period of less than six months with-
out evidence of clinical deterioration (n = 7); double pri-
mary cancer (n = 9); RT dose under 60 Gy (n = 13). The
reasons for dose reduction or discontinuing treatment
were poor general health (n = 6), patient refusal (n = 5),
and unknown (n = 2). A total of 83 patients were ana-
lyzed. Pretreatment evaluations included chest X-ray,
chest computed tomography (CT), bronchoscopy, PET-
CT, brain CT or magnetic resonance (MR), bone scan,
mediastinoscopy or endobronchial ultrasound (EBUS),
and pulmonary function testing. The performance status
in each case was assessed using the Eastern Cooperative
Oncology Group (ECOG) scale.
Radiation therapy
Radiation was only targeted to the primary tumor and
clinically involved lymph nodes. A lymph node was in-
cluded in the gross tumor volume (GTV) if it was
greater than 1 cm on its short axis by CT analysis, had
an increased standard uptake value on 18FDG-PET, or
was biopsy-positive. Elective nodal irradiation was not
performed for any of our subjects. A total dose of 66 Gy
was administered in 30 fractions (2.2 Gy/fraction) and
delivered once daily (five times per week) with 4 to 6 co-
planar and/or non-coplanar beams. In rare instances, the
fraction sizes were adjusted from 1.8 to 3 Gy, in accord-
ance with the tumor and patient characteristics. Later in
study period, four-dimensional computed tomography
(CT) was used to track tumor motion, and respiratory
gating was used when tumor moves more than 1 cm
during treatment.
Follow-up and definition of recurrence
One month after completing RT, the tumor response
was evaluated in each patient using CT scanning based
on the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria. Regular follow-ups were performed
that included a physical examination, complete blood
count, chest X-ray, and chest CT. A follow-up was per-
formed every three months for the first two years and
then every six months thereafter. Local recurrence was
defined as an increase in tumor size or tumor regrowth
in radiation field that was not believed to be radiation-
induced pneumonitis or fibrosis. It was comprehensively
determined by radiologist and radiation oncologist.
Distant metastasis was defined as a lymph node recur-
rence outside of the radiation field, a lung metastasis, or
a metastasis to an extra-thoracic site. Radiation-related
toxicities, esophagitis, and pneumonitis were recorded
based on the Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0 (20).
Statistical analyses
Time was calculated from the date of RT start to the
event. For local- and distant control rates, time to first
recurrence was considered whereas for local- and
distant-recurrence free survival, both time to first failure
or death were considered as events. Survival rates were
estimated using the Kaplan–Meier method. Univariate
and multivariate analyses to assess predictors of sur-
vival were performed using a log-rank test and the Cox
proportional hazard model. All statistical analyses were




The baseline characteristics of the study patients are
listed in Table 1. Median age of patients was 73 years
(range, 60 – 82 years), with 60 % of patients aged over
75 years. Sixty-six patients (80 %) had a history of smok-
ing. Seventy-one patients (86 %) had stage III disease,
and 17 had tumor larger than 7 cm in size. Fourty-eight
percent of patients had ECOG PS 2 or 3. The most com-
mon reason for omission for the chemotherapy was poor
performance status (n = 37). Other reasons included
poor lung function (n = 33), cardiac disease (n = 7),
patent’s refusal (n = 5), and cerebrovascular disease (n = 1).
Treatment and initial tumor response
Among the 83 patients in our study cohort, 77 (93 %)
patients were treated using a 66 Gy at 2.2 Gy/fraction
schedule, among whom 75 patients completed the
course of treatment. The treatment completion rate was
97 % and the other 2 patients received 61.6 Gy. Other
patients received 60 Gy at 3 Gy/fraction (n = 4), 65.6 Gy
at 2.1 Gy/fraction (n = 1), or 70.4 Gy at 2.2 Gy/fraction
(n = 1). Intensity-modulated RT was used in 3 (4 %) pa-
tients. After one month, the overall response rate was
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59 %. Based on RECIST criteria, complete response
(CR), partial response (PR), stable disease (SD), and pro-
gressive disease (PD) were observed in 4 (5 %), 45
(54 %), 31 (37 %), and 3 (4 %) patients, respectively.
Survival outcomes and patterns of treatment failure
The median follow-up period was 70 months (range,
42 – 135) for surviving patients and 17 months
(range, 2 – 135) for the whole group. The median
survival time was 18.6 months (range, 2–135) for all
patients. For stage II and III patients, median survival
time was 24.0 months and 18.3 months, respectively.
The actuarial overall survival (OS) rates at 2 and
3 years were 39 % and 23 %, respectively (Fig. 1a).
The cause of death was intercurrent disease in 13 pa-
tients. The cause-specific survival (CSS) rate at 2 and
3 years were 57 % and 47 %, respectively. First recur-
rences occurred locally in 24 (29 %) patients, distantly
in 18 (22 %) patients, and simultaneously in 5 (6 %)
patients. The 2- and 3-year local control rate was
57 %, and local recurrence-free survival rates were
29 % and 18 %, respectively. The progression-free sur-
vival (PFS) rates at 2 and 3 years were 23 % and
17 %, respectively (Fig. 1b).
Local control was significantly associated to lung
cancer-specific survival. When primary tumor was con-
trolled, the 2- and 3-year CSS were 56 % and 45 %, but
32 % and 23 % in those patients with local failure, re-
spectively (P = 0.02; Fig. 2). The corresponding values
for OS was 43 %, 26 % and 31 %, 17 % (P = 0.45). Pos-
sibly due to small patient number, the local control-
lability failed to show statistically significant difference
in OS in this study. Initial tumor response after com-
pleting RT was associated with local control. The local
control rates at 3 years in the CR/PR and SD/PD pa-
tients were 68 % and 39 %, respectively (P = 0.01; Fig. 3).
High local control rate of good responders resulted in
trends toward better PFS. The PFS at 2 years in the
CR/PR and SD/PD patients were 29 % and 15 %,
respectively (P = 0.11). The 2- and 3-year distant
metastasis-free survival rates were 33 % and 22 %, re-
spectively. Sites of metastases included the lung (n = 9),
liver (n = 5), brain (n = 3), bone (n = 3), adrenal gland
(n = 1), multiple sites (n = 2). Salvage therapies for dis-
tant metastasis included chemotherapy in 11 patients,
RT in 7 patients, and best supportive care in 5. Eleven
patients whom salvage chemotherapy has applied to did
initially not receive combination treatment, because of
poor performance status or underlying disease (n = 7),
poor lung function (n = 2) or patient’s refusal (n = 2).
With caution, palliative chemotherapy with single or
double regimen could be administered.
For prognostic factor analysis, age (<75 years vs. ≥
75 years), sex, ECOG performance status, FEV1(%),
Table 1 Patient characteristics
Characteristics No. of patients (%)










Mean FEV1 (L) 1.75
Mean FEV1 (%) 72

















Tumor size, mean (cm) 5.0 (1.5 – 12.5)
<7 cm 66 (80)
≥7 cm 17 (20)
Reasons for RT alone
Poor performance 37 (45)
Poor lung function 33 (40)
Cardiac disease 7 (8)
Patient refusal 5 (6)
Cerebrovascular disease 1 (1)
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status, FEV1 forced expiratory volume in one second, DLCO diffusing capacity
of carbon monoxide, NOS not otherwise specified, AJCC American Joint
Committee on Cancer, UICC International Union Against Cancer
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pathology, tumor size (<7 cm vs. ≥ 7 cm), T- and N-
stage, and initial response (CR/PR vs. SD/PD) were
examined. Univariate and multivariate analysis of prog-
nostic factors are summarized in Tables 2 and 3, re-
spectively. Initial response after RT was the only
significant factor for both PFS and CSS on multivari-
ate analysis. None of the factors examined had differ-
ence in OS, but, good responders after RT showed
trends toward better OS (hazard ratio: 1.68, confi-
dence interval: 0.96-2.94, P = 0.07).
Treatment-related toxicities
None of the patients analyzed experienced greater than
grade 3 esophagitis. Grade 2 esophagitis was observed in
49 (59 %) cases. Grade 3 pneumonitis occurred in 2
(2 %) patients, and these symptoms were controllable.
Grade 2 pneumonitis was observed in 11 (13 %) patients.
Acute RT complications were more prominent among
the older age group (≥75 years) than among the younger
patients (<75 years), but the difference was not signifi-
cant. Symptomatic esophagitis rate was 58 % vs. 60 %
(P = 0.81), and acute RT pneumonitis rate was 10 %
vs. 24 % (P = 0.08). Grade 3 pneumonitis (n = 2) was
observed in patients older than 75 years.
Discussion
The incidence of NSCLC in elderly patients is increasing
worldwide, and the proportion of very elderly patients
(80 years old or older) is also increasing [2]. Thus, there
has been a growing interest in treatment of NSCLC, for
patients who cannot tolerate chemotherapy. Radiation
Fig. 1 a Overall survival outcomes in the study patients. At 2 and 3 years these were estimated at 39 % and 23 %, respectively. b Progression-free
survival outcomes in the study patients. The rates at 2 and 3 years were 23 % and 17 %, respectively
Fig. 2 Cause-specific survivals in accordance with local tumor
control. The 2- and 3-year cause-specific survival rates were 56 %
and 45 %, respectively, in patients in whom the primary tumor
was controlled, and 32 % and 23 %, respectively, in those patients with
local failure (P = 0.02)
Fig. 3 Local control rates in accordance with the initial tumor
response. The local control rates at 3 years in the complete
response/partial response group and stable disease/progressive
disease patients were 68 % and 39 %, respectively (P = 0.01)
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remains an attractive option either alone or combined
with chemotherapy for those patients in whom a medical
condition precludes surgery. The necessity for prospect-
ive trials designed for elderly is controversial. Some
authors argue that elderly patients do as well as their
younger counterparts, and cite retrospective data as evi-
dence. The North Central Cancer Treatment Group
(NCCTG) performed a retrospective study on 246 pa-
tients to examine the relationship between patient age and
clinical outcomes. They found that elderly (≥70 years) pa-
tients had survival rates that were equivalent to those of
younger individuals, except for higher hematological tox-
icity and pneumonitis rates (81 % vs. 62 %, P = 0.01).
Hence, it has been argued that fit, elderly patients with lo-
cally advanced NSCLC should receive a combined-
modality therapy with cautious and judicious monitoring
[6, 11]. Growing evidence supports that aggressive treat-
ment will have benefit in survival, even in elderly NSCLC
patients [11–14]. But, it is obvious that elderly patients are
generally not treated using a combined-modality therapy.
In population-based studies of elderly patients with locally
advanced NSCLC, only 30–45 % of all treated patients
were subjected to chemotherapy [15, 16]. Thus, attempts
to evaluate treatment outcomes for patients with locally
advanced NSCLC treated using RT alone are necessary.
Median age of the patients included in current study is
73 years, 60 % of patients are 75 years or older, and all
of the patients were over 60 years old. In addition, half
of the patients were unsuitable for chemotherapy be-
cause of underlying medical condition, as well as their
Table 2 Univariate analysis of prognostic factors that influence PFS, CSS, and OS
Characteristics PFS CSS OS
N 2-year rate P-value 2-year rate P-value 2-year rate P-value
Age 0.62 0.43 0.58
<75 50 20 54 40
≥75 33 27 61 36
Sex 0.82 0.49 0.86
M 75 23 43 39
F 8 25 64 38
ECOG PS 0.53 0.28 0.20
0-1 43 23 59 44
2-3 40 23 53 33
aFEV1(%) 0.84 0.96 0.69
≥70 45 22 50 47
<70 33 24 46 40
Pathology 0.81 0.92 0.71
Squamous cell carcinoma 62 24 60 63
Adenocarcinoma 13 23 35 23
Others 8 13 60 38
Tumor size 0.32 0.9 0.37
<7 c m 66 18 57 36
≥7 c m 17 41 55 47
T-stage 0.14 0.13 0.2
1-2 33 27 63 39
3-4 50 20 53 38
N-stage 0.55 0.67 0.55
0-1 27 30 64 44
2-3 56 20 53 36
Initial response 0.11 0.07 0.17
CR or PR 49 29 71 49
SD or PD 34 15 35 24
Abbreviations: PFS progession-free survival, CSS cause-specific survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group performance status, FEV1
forced expiratory volume in one second, CR complete response, PR partial response, SD stable disease, PD progressive disease
aFEV1 test was not performed in 5 patients
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poor performance status. Therefore, by reviewing the
treatment results of our study cohort, we can predict
treatment outcomes of RT alone in NSCLC for elderly
patients.
In this study, we present survival outcomes in stage II-
III NSCLC patients who were treated with RT alone
using modern techniques. Treatment effectiveness of
radical RT in stage I/II (T1-2/N0-1 or T3N0) medically
inoperable NSCLC were summarized by Rowell et al., in
Cochrane database systematic review. Two-year overall
survival was 22-72 %, and median survival was 15–33
months. For patients with poor performance status, the
median survival was 6–13 months. This result is poorly
applied to modern treatment era, as total dose was low
(≥40 Gy) and mediastinal irradiation was used. [17]. Pre-
viously reported survival outcome of stage III NSCLC
patients who were treated by RT alone was relatively
poor, despite high irradiated dose. Sigel et al. analyzed
treatment outcome of stage III NSCLC patients using
the Surveillance, Epidemiology and End Results (SEER)
registry, treated between 1992 and 2007. The median OS
time was 9.0 months. The survival was better when
using high complexity RT, but survival time was not pre-
sented separately [18]. In phase III intergroup study by
Radiation Therapy Oncology Group, Eastern Coopera-
tive Oncology Group, and Southwest Oncology Group,
median OS of stage III NSCLC patients treated by lone
RT was 11.4 months for standard RT arm (60 Gy) and
Table 3 Multivariate analysis of prognostic factors that influence PFS, CSS, and OS
PFS CSS OS
Characteristics HR (95 % CI) P-value HR (95 % CI) P-value HR (95 % CI) P-value
Age 0.42 0.32 0.96
<75 1 1 1
≥75 0.82 (0.51-1.33) 0.70 (0.34-1.42) 1.01 (0.62-1.66)
Sex 0.66 0.81 0.86
M 1 1 1
F 0.83 (0.35-1.94) 0.86 (0.24-3.08) 1.08 (0.45-2.58)
ECOG PS 0.27 0.14 0.90
0-1 1 1 1
2-3 1.33 (0.80-2.19) 1.66 (0.84-3.27) 1.56 (0.93-2.60)
aFEV1(%) 0.63 0.96 0.42
≥70 1 1 1
<70 0.88 (0.54-1.45) 1.02 (0.52-2.00) 0.81 (0.49-1.34)
Pathology
Squamous cell carcinoma 1 1 1
Adenocarcinoma 1.25 (0.56-2.79) 0.59 1.63 (0.62-4.29) 0.32 1.32 (0.60-2.91) 0.49
Others 0.93 (0.35-2.48) 0.88 0.70 (0.17-2.92) 0.63 0.78 (0.28-2.16) 0.64
Tumor size 0.11 0.50 0.20
<7 c m 1 1 1
≥7 c m 0.60 (0.32-1.11) 0.75 (0.33-1.72) 0.65 (0.34-1.25)
T-stage 0.02 0.12 0.08
1-2 1 1 1
3-4 2.00 (1.11-3.61) 1.90 (0.85-4.26) 1.67 (0.93-2.98)
N-stage 0.18 0.30 0.29
0-1 1 1 1
2-3 1.42 (0.85-2.39) 1.46 (0.72-2.97) 1.33 (0.79-2.26)
Initial response 0.02 0.02 0.07
CR or PR 1 1 1
SD or PD 2.03 (1.15-3.58) 2.40 (1.16-4.98) 1.68 (0.96-2.94)
Abbreviations: PFS progession-free survival, CSS cause-specific survival, OS overall survival, HR hazard ratio, 95 % CI 95 % confidence interval, ECOG PS Eastern
Cooperative Oncology Group performance status, FEV1 forced expiratory volume in one second, CR complete response, PR partial response, SD stable disease,
PD progressive disease
aFEV1 test was not performed in 5 patients
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12 months for hyperfractionated RT arm (69 Gy) [19]. In
our present study, the median survival time was
18.6 months for all patients and 18.3 months for the 71
patients with stage III NSCLC. For stage III patients,
2-year survival rate and CSS rate was 37 % and 54 %,
respectively. Despite the high proportion of patients
with poor performance status (48 % of patients had
ECOG ≥ 2), and old age (67 % of patients were aged
over 70 years), the survival outcome was not inferior
compared to previous reports of advanced NSCLC pa-
tients. This suggests that advances in RT techniques and
supportive care might contribute to improved survival.
Some studies have argued that patients over 70–75
years might have benefit in survival by radiation dose
over 40–50 Gy, which is considered inadequate in
normal definitive treatment. But, these results were
achieved mostly before modern RT technique era [20].
In a population-based study of elderly NSCLC patients,
improved survival rates were only shown when high
complexity RT approaches were used, and not for low
complexity RT [18]. A lot of reports have shown that
definitive RT dose over 60 Gy can be tolerated in older
patients, as well as younger patients, and our present
study result also confirms it. During study period, all
patients were treated with involved-field RT without
elective nodal irradiation. To reduce esophageal com-
plication, IGRT and IMRT were used in selected cases.
Respiratory gating during treatment time for minimal lung
irradiation was also used when indicated. With this ap-
proach, mild esophagitis during RT were complained in
59 % of patients, but no one required parenteral nutri-
tional support, tube feeding, or hospitalization. Symptom-
atic radiation pneumonitis was reported in 17 %, with 2
Grade 3 events. No grade 4+ toxicity was reported. After
careful evaluation of any concurrent illness in elderly
patients, definitive dose radiation can be administered
with caution. In comorbid or poor performance status
patients, total dose reduction or fractional dose reduc-
tion might be considered. Image-guided RT, intensity-
modulated RT, or respiratory gating will be helpful in
this regard. Stereotactic body radiation therapy (SBRT)
might also be a suitable treatment option for early stage
NSCLC. Stage IIA patients included in this study had
T1N1 or T2N1 disease, thus were not indicated for
SBRT. Treatment results using SBRT during same
period in our institution can be found in previously
published articles [21].
At the time of death, 27 of our patients exhibited evi-
dence of local recurrence. The patients in our series who
were successfully locally controlled showed improved
lung cancer-specific survival. It is evident that the sur-
vival of patients with NSCLC depends heavily on local/
regional tumor control. Recently, a retrospective analysis
of seven Radiation Therapy Oncology Group (RTOG)
prospective trials was reported. For advanced NSCLC
patients who were treated using chemo-radiotherapy,
there was a significant association reported between
loco-regional control and survival (hazard ratio, 1.43;
95 % confidence interval, 1.28–1.61; P < 0.0001) [22].
The importance of local control on overall survival can
also be observed from previous RT alone data. An im-
proved 5-year CSS was reported in patients in whom the
primary tumor was controlled (46 % vs. 12 %, P < 0.03)
[23]. Additionally, several retrospective results revealed
trends for increased local control followed by increased
survival [24–26]. The survival advantage in higher radi-
ation dose was also confirmed in elderly patients.
Lonardi et al. treated NSCLC patients aged over 75 years,
and found one-year survival rate of 28 % vs. 4 %, in pa-
tients given at least 50 Gy vs. in those treated with lower
doses [20]. Krol et al. reported that out of 108 medically
inoperable patients with NSCLC who were treated with
RT alone, 50 (52 %) cases with a CR achieved 5 years of
local relapse-free survival [27]. Among the patients in
CR in that study, only two had a regional recurrence as
the only site of relapse. Furthermore, Zhang et al. have
reported that patients achieving CR after RT had a high
OS rate and local control [10]. These results indicate
that long-term survival is associated with both local con-
trol and a robust initial tumor response. Thus, further
attempts including radiosensitizers and dose escalation
are necessary to improve RT response for patients who
are unfit for chemotherapy.
Our present study has several limitations associated
with its retrospective design. This study could not prove
a survival benefit of RT compared to other treatment
modalities. Given the fact that included patients were
not suitable for chemotherapy, the primary objective of
this work was to report the treatment outcomes after RT
alone in locally-advanced NSCLC patients who are unfit
for chemotherapy. Compared to previous studies, rela-
tively large number of patients and highly homogeneous
RT dose were used in this study. Also, they were treated
using modern techniques: 3D-CRT or IMRT, involved-
field RT, and a dose greater than 60 Gy.
Conclusions
Administering RT alone over 60 Gy for elderly NSCLC
patients showed promising results, although most of
these individuals experienced non-cancer-related med-
ical problems. Long-term disease control can be ex-
pected if an early tumor response to radiation is
achieved, which could result in improved OS rates.
To try to improve disease control and survival in elderly
patients, prospective studies of radiation dose-escalation
with RT alone can be considered in selected cases of lo-
cally advanced NSCLC.
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